25 XP   0   0   10

Xiangxue Pharmaceutical
Buy, Hold or Sell?

Let's analyse Xiangxue Pharmaceutical together

PenkeI guess you are interested in Xiangxue Pharmaceutical. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Xiangxue Pharmaceutical. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Xiangxue Pharmaceutical

I send you an email if I find something interesting about Xiangxue Pharmaceutical.

Quick analysis of Xiangxue Pharmaceutical (30 sec.)










What can you expect buying and holding a share of Xiangxue Pharmaceutical? (30 sec.)

How much money do you get?

How much money do you get?
¥0.15
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥4.26
Expected worth in 1 year
¥-1.42
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
¥-4.62
Return On Investment
-130.1%

For what price can you sell your share?

Current Price per Share
¥3.55
Expected price per share
¥3 - ¥4.74
How sure are you?
50%

1. Valuation of Xiangxue Pharmaceutical (5 min.)




Live pricePrice per Share (EOD)

¥3.55

Intrinsic Value Per Share

¥-4.22 - ¥8.07

Total Value Per Share

¥0.05 - ¥12.33

2. Growth of Xiangxue Pharmaceutical (5 min.)




Is Xiangxue Pharmaceutical growing?

Current yearPrevious yearGrowGrow %
How rich?$389.1m$518.9m-$129.7m-33.3%

How much money is Xiangxue Pharmaceutical making?

Current yearPrevious yearGrowGrow %
Making money-$73.6m-$95m$21.4m29.1%
Net Profit Margin-24.4%-23.2%--

How much money comes from the company's main activities?

3. Financial Health of Xiangxue Pharmaceutical (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#141 / 1011

Most Revenue
#48 / 1011

Most Profit
#936 / 1011

Most Efficient
#501 / 1011

What can you expect buying and holding a share of Xiangxue Pharmaceutical? (5 min.)

Welcome investor! Xiangxue Pharmaceutical's management wants to use your money to grow the business. In return you get a share of Xiangxue Pharmaceutical.

What can you expect buying and holding a share of Xiangxue Pharmaceutical?

First you should know what it really means to hold a share of Xiangxue Pharmaceutical. And how you can make/lose money.

Speculation

The Price per Share of Xiangxue Pharmaceutical is ¥3.55. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Xiangxue Pharmaceutical.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Xiangxue Pharmaceutical, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥4.26. Based on the TTM, the Book Value Change Per Share is ¥-1.42 per quarter. Based on the YOY, the Book Value Change Per Share is ¥-0.75 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.27 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Xiangxue Pharmaceutical.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps-0.11-3.1%-0.11-3.1%-0.14-4.0%-0.04-1.2%-0.01-0.2%
Usd Book Value Change Per Share-0.20-5.5%-0.20-5.5%-0.10-2.9%-0.04-1.3%0.030.8%
Usd Dividend Per Share0.041.0%0.041.0%0.051.3%0.041.2%0.041.1%
Usd Total Gains Per Share-0.16-4.5%-0.16-4.5%-0.06-1.6%0.000.0%0.061.8%
Usd Price Per Share0.84-0.84-1.11-1.05-1.58-
Price to Earnings Ratio-7.53--7.53--7.75-38.69-61.66-
Price-to-Total Gains Ratio-5.26--5.26--19.23-4.40-13.70-
Price to Book Ratio1.42-1.42-1.42-1.33-2.60-
Price-to-Total Gains Ratio-5.26--5.26--19.23-4.40-13.70-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.490255
Number of shares2039
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.040.04
Usd Book Value Change Per Share-0.20-0.04
Usd Total Gains Per Share-0.160.00
Gains per Quarter (2039 shares)-325.04-1.71
Gains per Year (2039 shares)-1,300.15-6.86
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1299-1600-1310356-363-17
2599-3199-2610711-725-24
3898-4799-39101067-1088-31
41198-6398-52101423-1450-38
51497-7998-65101779-1813-45
61797-9598-78102134-2176-52
72096-11197-91102490-2538-59
82396-12797-104102846-2901-66
92695-14396-117103202-3263-73
102994-15996-130103557-3626-80

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%8.02.00.080.0%14.02.00.087.5%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%8.02.00.080.0%14.02.00.087.5%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%16.00.00.0100.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%8.02.00.080.0%14.02.00.087.5%

Fundamentals of Xiangxue Pharmaceutical

About Xiangxue Pharmaceutical

Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, procurement, manufacture, delivery, and distribution of pharmaceutical products in China. It offers antivirotic oral liquids under the Xiangxue brand name; and healthcare supplements, as well as health solutions, such as food and beverage. Xiangxue Pharmaceutical Co., Ltd. has strategic partnership agreement with 111, Inc. to develop the Internet + Medicine model for China's traditional Chinese medicine industry. Xiangxue Pharmaceutical Co., Ltd. was founded in 1997 and is based in Guangzhou, China.

Fundamental data was last updated by Penke on 2024-04-16 12:35:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Xiangxue Pharmaceutical.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Xiangxue Pharmaceutical earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Xiangxue Pharmaceutical to the Biotechnology industry mean.
  • A Net Profit Margin of -24.4% means that ¥-0.24 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Xiangxue Pharmaceutical:

  • The MRQ is -24.4%. The company is making a huge loss. -2
  • The TTM is -24.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-24.4%TTM-24.4%0.0%
TTM-24.4%YOY-23.2%-1.2%
TTM-24.4%5Y-7.8%-16.6%
5Y-7.8%10Y0.5%-8.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24.4%-196.1%+171.7%
TTM-24.4%-211.9%+187.5%
YOY-23.2%-277.7%+254.5%
5Y-7.8%-432.9%+425.1%
10Y0.5%-599.3%+599.8%
1.1.2. Return on Assets

Shows how efficient Xiangxue Pharmaceutical is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Xiangxue Pharmaceutical to the Biotechnology industry mean.
  • -5.7% Return on Assets means that Xiangxue Pharmaceutical generated ¥-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Xiangxue Pharmaceutical:

  • The MRQ is -5.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.7%TTM-5.7%0.0%
TTM-5.7%YOY-6.0%+0.3%
TTM-5.7%5Y-1.8%-3.9%
5Y-1.8%10Y0.6%-2.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.7%-13.3%+7.6%
TTM-5.7%-12.7%+7.0%
YOY-6.0%-11.8%+5.8%
5Y-1.8%-14.0%+12.2%
10Y0.6%-15.9%+16.5%
1.1.3. Return on Equity

Shows how efficient Xiangxue Pharmaceutical is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Xiangxue Pharmaceutical to the Biotechnology industry mean.
  • -22.2% Return on Equity means Xiangxue Pharmaceutical generated ¥-0.22 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Xiangxue Pharmaceutical:

  • The MRQ is -22.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -22.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-22.2%TTM-22.2%0.0%
TTM-22.2%YOY-23.4%+1.2%
TTM-22.2%5Y-7.7%-14.4%
5Y-7.7%10Y-0.9%-6.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22.2%-16.9%-5.3%
TTM-22.2%-16.0%-6.2%
YOY-23.4%-15.1%-8.3%
5Y-7.7%-19.7%+12.0%
10Y-0.9%-20.5%+19.6%

1.2. Operating Efficiency of Xiangxue Pharmaceutical.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Xiangxue Pharmaceutical is operating .

  • Measures how much profit Xiangxue Pharmaceutical makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Xiangxue Pharmaceutical to the Biotechnology industry mean.
  • An Operating Margin of -6.7% means the company generated ¥-0.07  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Xiangxue Pharmaceutical:

  • The MRQ is -6.7%. The company is operating very inefficient. -2
  • The TTM is -6.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-6.7%TTM-6.7%0.0%
TTM-6.7%YOY-0.8%-5.9%
TTM-6.7%5Y4.0%-10.6%
5Y4.0%10Y5.2%-1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.7%-290.9%+284.2%
TTM-6.7%-224.4%+217.7%
YOY-0.8%-288.3%+287.5%
5Y4.0%-479.5%+483.5%
10Y5.2%-625.2%+630.4%
1.2.2. Operating Ratio

Measures how efficient Xiangxue Pharmaceutical is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.82 means that the operating costs are ¥1.82 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Xiangxue Pharmaceutical:

  • The MRQ is 1.819. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.819. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.819TTM1.8190.000
TTM1.819YOY1.722+0.096
TTM1.8195Y1.644+0.174
5Y1.64410Y1.400+0.245
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8193.110-1.291
TTM1.8193.266-1.447
YOY1.7223.783-2.061
5Y1.6445.657-4.013
10Y1.4007.783-6.383

1.3. Liquidity of Xiangxue Pharmaceutical.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Xiangxue Pharmaceutical is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.29 means the company has ¥0.29 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Xiangxue Pharmaceutical:

  • The MRQ is 0.289. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.289. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.289TTM0.2890.000
TTM0.289YOY0.444-0.155
TTM0.2895Y0.690-0.400
5Y0.69010Y0.963-0.273
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2893.905-3.616
TTM0.2894.212-3.923
YOY0.4445.337-4.893
5Y0.6906.062-5.372
10Y0.9636.401-5.438
1.3.2. Quick Ratio

Measures if Xiangxue Pharmaceutical is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Xiangxue Pharmaceutical to the Biotechnology industry mean.
  • A Quick Ratio of 0.10 means the company can pay off ¥0.10 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Xiangxue Pharmaceutical:

  • The MRQ is 0.103. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.103. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.103TTM0.1030.000
TTM0.103YOY0.235-0.132
TTM0.1035Y0.317-0.214
5Y0.31710Y0.541-0.224
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1033.572-3.469
TTM0.1034.001-3.898
YOY0.2355.364-5.129
5Y0.3176.009-5.692
10Y0.5416.287-5.746

1.4. Solvency of Xiangxue Pharmaceutical.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Xiangxue Pharmaceutical assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Xiangxue Pharmaceutical to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.70 means that Xiangxue Pharmaceutical assets are financed with 69.9% credit (debt) and the remaining percentage (100% - 69.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Xiangxue Pharmaceutical:

  • The MRQ is 0.699. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.699. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.699TTM0.6990.000
TTM0.699YOY0.670+0.029
TTM0.6995Y0.591+0.107
5Y0.59110Y0.530+0.061
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6990.336+0.363
TTM0.6990.334+0.365
YOY0.6700.271+0.399
5Y0.5910.366+0.225
10Y0.5300.389+0.141
1.4.2. Debt to Equity Ratio

Measures if Xiangxue Pharmaceutical is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Xiangxue Pharmaceutical to the Biotechnology industry mean.
  • A Debt to Equity ratio of 271.7% means that company has ¥2.72 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Xiangxue Pharmaceutical:

  • The MRQ is 2.717. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.717. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.717TTM2.7170.000
TTM2.717YOY2.588+0.129
TTM2.7175Y1.861+0.856
5Y1.86110Y1.453+0.408
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7170.382+2.335
TTM2.7170.397+2.320
YOY2.5880.341+2.247
5Y1.8610.432+1.429
10Y1.4530.465+0.988

2. Market Valuation of Xiangxue Pharmaceutical

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Xiangxue Pharmaceutical generates.

  • Above 15 is considered overpriced but always compare Xiangxue Pharmaceutical to the Biotechnology industry mean.
  • A PE ratio of -7.53 means the investor is paying ¥-7.53 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Xiangxue Pharmaceutical:

  • The EOD is -4.403. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.529. Based on the earnings, the company is expensive. -2
  • The TTM is -7.529. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.403MRQ-7.529+3.126
MRQ-7.529TTM-7.5290.000
TTM-7.529YOY-7.752+0.224
TTM-7.5295Y38.686-46.214
5Y38.68610Y61.663-22.977
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.403-2.262-2.141
MRQ-7.529-2.599-4.930
TTM-7.529-2.674-4.855
YOY-7.752-4.133-3.619
5Y38.686-6.258+44.944
10Y61.663-6.171+67.834
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Xiangxue Pharmaceutical:

  • The EOD is -16.781. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -28.693. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -28.693. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-16.781MRQ-28.693+11.912
MRQ-28.693TTM-28.6930.000
TTM-28.693YOY-17.489-11.205
TTM-28.6935Y-15.632-13.062
5Y-15.63210Y68.709-84.341
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-16.781-2.913-13.868
MRQ-28.693-3.275-25.418
TTM-28.693-3.508-25.185
YOY-17.489-5.620-11.869
5Y-15.632-8.306-7.326
10Y68.709-8.854+77.563
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Xiangxue Pharmaceutical is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.42 means the investor is paying ¥1.42 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Xiangxue Pharmaceutical:

  • The EOD is 0.833. Based on the equity, the company is cheap. +2
  • The MRQ is 1.424. Based on the equity, the company is underpriced. +1
  • The TTM is 1.424. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.833MRQ1.424-0.591
MRQ1.424TTM1.4240.000
TTM1.424YOY1.420+0.004
TTM1.4245Y1.334+0.090
5Y1.33410Y2.601-1.267
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.8331.858-1.025
MRQ1.4242.090-0.666
TTM1.4242.091-0.667
YOY1.4202.866-1.446
5Y1.3343.488-2.154
10Y2.6013.836-1.235
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Xiangxue Pharmaceutical compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.420-1.4200%-0.748-47%-0.322-77%0.194-833%
Book Value Per Share--4.2624.2620%5.682-25%5.734-26%5.089-16%
Current Ratio--0.2890.2890%0.444-35%0.690-58%0.963-70%
Debt To Asset Ratio--0.6990.6990%0.670+4%0.591+18%0.530+32%
Debt To Equity Ratio--2.7172.7170%2.588+5%1.861+46%1.453+87%
Dividend Per Share--0.2660.2660%0.328-19%0.316-16%0.273-3%
Eps---0.806-0.8060%-1.041+29%-0.299-63%-0.049-94%
Free Cash Flow Per Share---0.212-0.2120%-0.461+118%-0.595+181%-0.694+228%
Free Cash Flow To Equity Per Share---1.199-1.1990%-1.142-5%-1.114-7%-0.353-71%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--8.072--------
Intrinsic Value_10Y_min---4.216--------
Intrinsic Value_1Y_max---0.180--------
Intrinsic Value_1Y_min---0.632--------
Intrinsic Value_3Y_max--0.213--------
Intrinsic Value_3Y_min---1.728--------
Intrinsic Value_5Y_max--1.514--------
Intrinsic Value_5Y_min---2.630--------
Market Cap2347540364.800-71%4013963803.1504013963803.1500%5337186780.450-25%5038701761.370-20%7550730132.019-47%
Net Profit Margin---0.244-0.2440%-0.232-5%-0.078-68%0.005-4793%
Operating Margin---0.067-0.0670%-0.008-89%0.040-269%0.052-229%
Operating Ratio--1.8191.8190%1.722+6%1.644+11%1.400+30%
Pb Ratio0.833-71%1.4241.4240%1.420+0%1.334+7%2.601-45%
Pe Ratio-4.403+42%-7.529-7.5290%-7.752+3%38.686-119%61.663-112%
Price Per Share3.550-71%6.0706.0700%8.070-25%7.618-20%11.417-47%
Price To Free Cash Flow Ratio-16.781+42%-28.693-28.6930%-17.489-39%-15.632-46%68.709-142%
Price To Total Gains Ratio-3.075+42%-5.259-5.2590%-19.226+266%4.401-219%13.703-138%
Quick Ratio--0.1030.1030%0.235-56%0.317-68%0.541-81%
Return On Assets---0.057-0.0570%-0.060+6%-0.018-68%0.006-997%
Return On Equity---0.222-0.2220%-0.234+5%-0.077-65%-0.009-96%
Total Gains Per Share---1.154-1.1540%-0.420-64%-0.006-99%0.467-347%
Usd Book Value--389190902.052389190902.0520%518949169.477-25%523715450.834-26%464799579.913-16%
Usd Book Value Change Per Share---0.196-0.1960%-0.103-47%-0.044-77%0.027-833%
Usd Book Value Per Share--0.5890.5890%0.785-25%0.792-26%0.703-16%
Usd Dividend Per Share--0.0370.0370%0.045-19%0.044-16%0.038-3%
Usd Eps---0.111-0.1110%-0.144+29%-0.041-63%-0.007-94%
Usd Free Cash Flow---19319057.699-19319057.6990%-42144930.542+118%-54330083.993+181%-63366784.291+228%
Usd Free Cash Flow Per Share---0.029-0.0290%-0.064+118%-0.082+181%-0.096+228%
Usd Free Cash Flow To Equity Per Share---0.166-0.1660%-0.158-5%-0.154-7%-0.049-71%
Usd Market Cap324195324.379-71%554328401.215554328401.2150%737065494.380-25%695844713.245-20%1042755831.232-47%
Usd Price Per Share0.490-71%0.8380.8380%1.114-25%1.052-20%1.577-47%
Usd Profit---73629182.902-73629182.9020%-95077588.984+29%-27113747.233-63%-4382887.703-94%
Usd Revenue--302034353.383302034353.3830%410236523.768-26%373427599.851-19%301146859.297+0%
Usd Total Gains Per Share---0.159-0.1590%-0.058-64%-0.001-99%0.064-347%
 EOD+3 -5MRQTTM+0 -0YOY+11 -245Y+6 -2910Y+8 -27

3.2. Fundamental Score

Let's check the fundamental score of Xiangxue Pharmaceutical based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.403
Price to Book Ratio (EOD)Between0-10.833
Net Profit Margin (MRQ)Greater than0-0.244
Operating Margin (MRQ)Greater than0-0.067
Quick Ratio (MRQ)Greater than10.103
Current Ratio (MRQ)Greater than10.289
Debt to Asset Ratio (MRQ)Less than10.699
Debt to Equity Ratio (MRQ)Less than12.717
Return on Equity (MRQ)Greater than0.15-0.222
Return on Assets (MRQ)Greater than0.05-0.057
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Xiangxue Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.221
Ma 20Greater thanMa 503.971
Ma 50Greater thanMa 1003.937
Ma 100Greater thanMa 2004.574
OpenGreater thanClose3.450
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Retained Earnings  703,41997,733801,15224,582825,734-687,319138,416-533,158-394,743
Operating Income  293,627-71,954221,673142,618364,292-319,19745,094-191,439-146,345



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets9,353,001
Total Liabilities6,534,819
Total Stockholder Equity2,405,133
 As reported
Total Liabilities 6,534,819
Total Stockholder Equity+ 2,405,133
Total Assets = 9,353,001

Assets

Total Assets9,353,001
Total Current Assets1,693,187
Long-term Assets7,659,813
Total Current Assets
Cash And Cash Equivalents 166,503
Short-term Investments 126
Net Receivables 599,987
Inventory 467,075
Other Current Assets 88,183
Total Current Assets  (as reported)1,693,187
Total Current Assets  (calculated)1,321,874
+/- 371,313
Long-term Assets
Property Plant Equipment 5,525,483
Goodwill 199,720
Intangible Assets 1,367,021
Other Assets 497,906
Long-term Assets  (as reported)7,659,813
Long-term Assets  (calculated)7,590,130
+/- 69,683

Liabilities & Shareholders' Equity

Total Current Liabilities5,852,556
Long-term Liabilities682,263
Total Stockholder Equity2,405,133
Total Current Liabilities
Short Long Term Debt 1,926,083
Accounts payable 841,313
Other Current Liabilities 2,970,907
Total Current Liabilities  (as reported)5,852,556
Total Current Liabilities  (calculated)5,738,303
+/- 114,253
Long-term Liabilities
Other Liabilities 230,412
Deferred Long Term Liability 440,651
Long-term Liabilities  (as reported)682,263
Long-term Liabilities  (calculated)671,063
+/- 11,199
Total Stockholder Equity
Common Stock661,279
Other Stockholders Equity -5,193
Total Stockholder Equity (as reported)2,405,133
Total Stockholder Equity (calculated)656,086
+/- 1,749,047
Other
Capital Stock661,279
Common Stock Shares Outstanding 661,279
Net Debt 2,186,511
Net Invested Capital 4,758,147
Net Working Capital -4,159,369
Property Plant and Equipment Gross 5,525,483



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-31
> Total Assets 
553,433
551,471
698,315
1,846,628
1,921,138
2,949,032
3,474,708
3,588,283
4,652,002
7,988,727
9,240,687
8,625,609
8,063,293
9,778,169
11,380,592
9,353,001
9,353,00111,380,5929,778,1698,063,2938,625,6099,240,6877,988,7274,652,0023,588,2833,474,7082,949,0321,921,1381,846,628698,315551,471553,433
   > Total Current Assets 
0
0
0
0
0
0
0
0
2,127,574
2,980,809
4,872,380
3,918,586
3,099,830
3,731,358
3,086,002
1,693,187
1,693,1873,086,0023,731,3583,099,8303,918,5864,872,3802,980,8092,127,57400000000
       Cash And Cash Equivalents 
44,473
40,072
89,083
1,152,254
785,986
1,289,427
761,209
334,412
657,333
835,787
1,413,791
650,107
495,694
605,136
196,122
166,503
166,503196,122605,136495,694650,1071,413,791835,787657,333334,412761,2091,289,427785,9861,152,25489,08340,07244,473
       Short-term Investments 
0
0
0
0
0
0
0
0
317,780
26,364
593,680
23,337
28,544
19,337
65,626
126
12665,62619,33728,54423,337593,68026,364317,78000000000
       Net Receivables 
15,843
29,701
66,508
94,425
100,546
183,797
405,129
506,190
679,586
1,151,734
2,172,708
2,037,066
1,440,339
1,039,040
1,566,476
599,987
599,9871,566,4761,039,0401,440,3392,037,0662,172,7081,151,734679,586506,190405,129183,797100,54694,42566,50829,70115,843
       Inventory 
19,817
23,604
30,243
54,221
89,353
128,726
224,592
284,296
341,750
503,133
504,547
590,062
756,406
839,810
761,464
467,075
467,075761,464839,810756,406590,062504,547503,133341,750284,296224,592128,72689,35354,22130,24323,60419,817
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
5,007,918
4,368,307
4,707,023
5,363,239
6,057,449
8,294,590
7,659,813
7,659,8138,294,5906,057,4495,363,2394,707,0234,368,3075,007,918000000000
       Property Plant Equipment 
401,127
417,743
458,681
496,800
760,552
1,129,559
1,433,435
1,481,557
1,620,878
2,866,060
2,399,870
2,683,417
3,293,122
3,488,702
5,955,784
5,525,483
5,525,4835,955,7843,488,7023,293,1222,683,4172,399,8702,866,0601,620,8781,481,5571,433,4351,129,559760,552496,800458,681417,743401,127
       Goodwill 
0
0
0
0
0
0
0
422,528
422,528
634,536
646,661
644,667
626,610
626,610
266,597
199,720
199,720266,597626,610626,610644,667646,661634,536422,528422,5280000000
       Long Term Investments 
0
0
0
0
0
0
0
0
157,158
269,610
334,890
366,193
0
0
0
0
0000366,193334,890269,610157,15800000000
       Intangible Assets 
48,442
13,621
0
10,486
33,712
32,411
40,492
601,585
238,415
401,167
559,822
778,351
721,627
973,961
1,429,770
1,367,021
1,367,0211,429,770973,961721,627778,351559,822401,167238,415601,58540,49232,41133,71210,486013,62148,442
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
802,942
385,100
187,388
217,614
241,512
69,476
30,950
30,95069,476241,512217,614187,388385,100802,942000000000
> Total Liabilities 
361,983
354,936
360,690
476,010
502,161
1,412,466
1,764,699
1,717,076
1,106,022
4,304,373
5,356,955
4,613,340
3,943,099
5,525,135
7,622,814
6,534,819
6,534,8197,622,8145,525,1353,943,0994,613,3405,356,9554,304,3731,106,0221,717,0761,764,6991,412,466502,161476,010360,690354,936361,983
   > Total Current Liabilities 
136,444
265,986
291,520
403,796
294,418
707,316
1,018,166
1,137,349
563,858
3,301,139
3,235,466
3,222,436
3,263,107
6,802,345
6,944,299
5,852,556
5,852,5566,944,2996,802,3453,263,1073,222,4363,235,4663,301,139563,8581,137,3491,018,166707,316294,418403,796291,520265,986136,444
       Short-term Debt 
0
0
0
0
0
0
0
0
0
1,095,000
1,649,381
1,463,100
0
0
0
0
00001,463,1001,649,3811,095,000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
1,095,000
1,649,381
1,463,100
1,410,500
2,881,304
2,466,299
1,926,083
1,926,0832,466,2992,881,3041,410,5001,463,1001,649,3811,095,000000000000
       Accounts payable 
39,260
118,724
76,182
79,182
79,357
110,271
221,308
250,067
238,909
517,604
461,056
451,436
707,721
801,001
1,122,753
841,313
841,3131,122,753801,001707,721451,436461,056517,604238,909250,067221,308110,27179,35779,18276,182118,72439,260
       Other Current Liabilities 
46,284
53,262
74,838
64,614
62,561
83,045
382,858
252,282
252,221
394,054
320,952
400,763
768,645
2,924,231
2,831,923
2,970,907
2,970,9072,831,9232,924,231768,645400,763320,952394,054252,221252,282382,85883,04562,56164,61474,83853,26246,284
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
1,003,234
2,121,489
1,390,904
1,076,904
1,145,108
678,516
682,263
682,263678,5161,145,1081,076,9041,390,9042,121,4891,003,234000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
-1,095,000
-1,649,381
-1,463,100
0
2,322
2,359
24,919
24,9192,3592,3220-1,463,100-1,649,381-1,095,000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
754,000
1,821,696
1,308,419
938,205
36,064
16,580
49,630
49,63016,58036,064938,2051,308,4191,821,696754,000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
75,340
150,515
194,151
106,691
158,854
395,456
429,514
440,651
440,651429,514395,456158,854106,691194,151150,51575,34000000000
> Total Stockholder Equity
178,937
182,096
320,545
1,347,639
1,394,138
1,483,319
1,605,437
1,743,892
3,407,686
3,396,596
3,461,903
3,430,591
3,496,996
3,616,536
2,945,553
2,405,133
2,405,1332,945,5533,616,5363,496,9963,430,5913,461,9033,396,5963,407,6861,743,8921,605,4371,483,3191,394,1381,347,639320,545182,096178,937
   Common Stock
81,000
81,000
92,000
123,000
246,000
300,973
392,055
509,573
661,476
661,476
661,476
661,476
661,476
661,476
661,361
661,279
661,279661,361661,476661,476661,476661,476661,476661,476509,573392,055300,973246,000123,00092,00081,00081,000
   Retained Earnings 
72,757
72,715
118,609
135,230
173,693
222,571
309,965
505,729
614,234
600,881
666,820
703,419
801,152
825,734
138,416
-394,743
-394,743138,416825,734801,152703,419666,820600,881614,234505,729309,965222,571173,693135,230118,60972,71572,757
   Capital Surplus 0000000000000000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
-2,442
-65
-719
3,256
-36,454
4,204
2,068
-5,193
-5,1932,0684,204-36,4543,256-719-65-2,44200000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,169,651
Cost of Revenue-1,431,880
Gross Profit737,770737,770
 
Operating Income (+$)
Gross Profit737,770
Operating Expense-2,067,675
Operating Income101,975-1,329,905
 
Operating Expense (+$)
Research Development76,083
Selling General Administrative389,048
Selling And Marketing Expenses-
Operating Expense2,067,675465,131
 
Net Interest Income (+$)
Interest Income4,136
Interest Expense-225,797
Other Finance Cost-8,951
Net Interest Income-230,612
 
Pretax Income (+$)
Operating Income101,975
Net Interest Income-230,612
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-371,441101,975
EBIT - interestExpense = -225,797
-380,573
-154,776
Interest Expense225,797
Earnings Before Interest and Taxes (EBIT)--145,645
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-371,441
Tax Provision--5,553
Net Income From Continuing Ops-365,888-365,888
Net Income-380,573
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-230,612
 

Technical Analysis of Xiangxue Pharmaceutical
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Xiangxue Pharmaceutical. The general trend of Xiangxue Pharmaceutical is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Xiangxue Pharmaceutical's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Xiangxue Pharmaceutical.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.65 < 3.7 < 4.74.

The bearish price targets are: 3.32 > 3 > 3.

Tweet this
Xiangxue Pharmaceutical Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Xiangxue Pharmaceutical. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Xiangxue Pharmaceutical Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Xiangxue Pharmaceutical. The current macd is -0.20143293.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Xiangxue Pharmaceutical price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Xiangxue Pharmaceutical. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Xiangxue Pharmaceutical price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Xiangxue Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) ChartXiangxue Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Xiangxue Pharmaceutical. The current adx is 27.34.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Xiangxue Pharmaceutical shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Xiangxue Pharmaceutical Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Xiangxue Pharmaceutical. The current sar is 3.93543411.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Xiangxue Pharmaceutical Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Xiangxue Pharmaceutical. The current rsi is 39.22. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Xiangxue Pharmaceutical Daily Relative Strength Index (RSI) ChartXiangxue Pharmaceutical Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Xiangxue Pharmaceutical. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xiangxue Pharmaceutical price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Xiangxue Pharmaceutical Daily Stochastic Oscillator ChartXiangxue Pharmaceutical Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Xiangxue Pharmaceutical. The current cci is -88.43268851.

Xiangxue Pharmaceutical Daily Commodity Channel Index (CCI) ChartXiangxue Pharmaceutical Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Xiangxue Pharmaceutical. The current cmo is -24.39806318.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Xiangxue Pharmaceutical Daily Chande Momentum Oscillator (CMO) ChartXiangxue Pharmaceutical Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Xiangxue Pharmaceutical. The current willr is -80.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Xiangxue Pharmaceutical is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Xiangxue Pharmaceutical Daily Williams %R ChartXiangxue Pharmaceutical Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Xiangxue Pharmaceutical.

Xiangxue Pharmaceutical Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Xiangxue Pharmaceutical. The current atr is 0.21034334.

Xiangxue Pharmaceutical Daily Average True Range (ATR) ChartXiangxue Pharmaceutical Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Xiangxue Pharmaceutical. The current obv is 450,946,089.

Xiangxue Pharmaceutical Daily On-Balance Volume (OBV) ChartXiangxue Pharmaceutical Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Xiangxue Pharmaceutical. The current mfi is 30.72.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Xiangxue Pharmaceutical Daily Money Flow Index (MFI) ChartXiangxue Pharmaceutical Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Xiangxue Pharmaceutical.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Xiangxue Pharmaceutical Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Xiangxue Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.221
Ma 20Greater thanMa 503.971
Ma 50Greater thanMa 1003.937
Ma 100Greater thanMa 2004.574
OpenGreater thanClose3.450
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Xiangxue Pharmaceutical with someone you think should read this too:
  • Are you bullish or bearish on Xiangxue Pharmaceutical? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Xiangxue Pharmaceutical? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Xiangxue Pharmaceutical

I send you an email if I find something interesting about Xiangxue Pharmaceutical.


Comments

How you think about this?

Leave a comment

Stay informed about Xiangxue Pharmaceutical.

Receive notifications about Xiangxue Pharmaceutical in your mailbox!